menogaril

Summary

Summary: A semisynthetic anthracycline with the amino sugar on the D ring. It displays broad-spectrum antineoplastic activity against a variety of tumors.

Top Publications

  1. Ohe Y, Nakagawa K, Fujiwara Y, Sasaki Y, Minato K, Bungo M, et al. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines. Cancer Res. 1989;49:4098-102 pubmed
    ..The antitumor activities of KT6149, MX-2 (KRN8602), SM5887, menogaril (TUT-7), and liblomycin (NK313) were evaluated against four non-small cell lung cancer cell lines, PC-7, -9, -13,..
  2. Ettinger D, Finkelstein D, Abeloff M, Skeel R, Stott P, Frontiera M, et al. Justification for evaluating new anticancer drugs in selected untreated patients with extensive-stage small-cell lung cancer: an Eastern Cooperative Oncology Group randomized study. J Natl Cancer Inst. 1992;84:1077-84 pubmed
    ..4 mg/m2) every 3 weeks--or the phase II drug menogaril (200 mg/m2) every 4 weeks...
  3. Stewart D, Maroun J, Verma S, Perrault D, Earhart R. Phase I study of weekly intravenous administration of menogaril to adults with solid tumors. Am J Clin Oncol. 1989;12:511-8 pubmed
    Thirty-nine adults with solid tumors were treated on a Phase I study of menogaril administered i.v. once each week. Granulocytopenia was dose-limiting at a menogaril dose of 115 mg/m2/wk...
  4. Long H, Schaid D, Schutt A, Ingle J, Loprinzi C, Edmonson J. Phase II evaluation of menogaril in women with metastatic breast cancer after failure of first-line chemotherapy. Am J Clin Oncol. 1988;11:524-7 pubmed
    ..failed one prior chemotherapy regimen and had not received prior treatment with doxorubicin were treated with menogaril (200 mg/m2 i.v. over 1 h) every 4 weeks...
  5. Holdener E, ten Bokkel Huinink W, Decoster G, Ludwig C, Renard G, Pinedo H. Phase II trial of menogaril in advanced colorectal cancer. Invest New Drugs. 1988;6:227-30 pubmed
    b>Menogaril, a new semisynthetic anthracycline antibiotic, was administered to 35 patients with advanced colorectal cancer. The drug was infused over 2 hr at a dose of 160 mg/sqm or 200 mg/sqm repeated every 4 weeks...
  6. Li L, Krueger W. The biochemical pharmacology of nogalamycin and its derivatives. Pharmacol Ther. 1991;51:239-55 pubmed
    ..Among nogalamycin derivatives, menogaril showed distinct biochemical effects as well as superior cytotoxicity and antitumor activity and also proved to ..
  7. Long H, Wieand H, Foley J, Niedringhaus R, Laurie J, Morton R, et al. Phase II evaluation of menogaril in patients with advanced cervical carcinoma. A collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic. Invest New Drugs. 1991;9:349-51 pubmed
    Fourteen patients with advanced/recurrent squamous cell carcinoma of the uterine cervix received menogaril, 200 mg/m2 by one hour intravenous infusion at four-week intervals. No objective regressions were observed...
  8. Whitehead R, Earhart R, Fleming T, Goodman P, Macdonald J, Pollock T, et al. A phase II study of menogaril (NSC-269148) in colorectal carcinoma. A Southwest Oncology Group study. Invest New Drugs. 1990;8:295-7 pubmed
    In this phase II trial, menogaril was administered to patients with metastatic colon cancer at a dose of 200 mg/m2 IV over one hour with cycles repeated every 28 days provided the absolute granulocyte count was greater than or equal to ..
  9. Ogawa M, Ariyoshi Y. [New anthracyclines]. Gan To Kagaku Ryoho. 1993;20:27-33 pubmed
    ..Phase II trials of anthrapyrazoles which is an analog of mitoxantrone are in progress. Among three compounds entered it is of note that CI-941 has demonstrated an excellent activity against advanced breast cancer. ..

More Information

Publications42

  1. Wierzba K, Sugimoto Y, Matsuo K, Toko T, Takeda S, Yamada Y, et al. Menogaril, an anthracycline compound with a novel mechanism of action: cellular pharmacology. Jpn J Cancer Res. 1990;81:842-9 pubmed
    b>Menogaril, an anthracycline compound possessing a significant antitumor activity after both po and iv administration, has been introduced into clinical trials. However, its mechanism of action has not been clarified yet...
  2. Dodion P, de Valeriola D, Crespeigne N, Peeters B, Wery F, van Berchem C, et al. Phase I clinical and pharmacokinetic trial of oral menogaril administered on three consecutive days. Eur J Cancer Clin Oncol. 1988;24:1019-26 pubmed
    Eighteen adult patients with solid tumors were treated with oral menogaril, a new anthracycline antibiotic active against human breast cancer after intravenous administration...
  3. Sessa C, Gundersen S, ten Bokkel Huinink W, Renard J, Cavalli F. Phase II study of intravenous menogaril in patients with advanced breast cancer. J Natl Cancer Inst. 1988;80:1066-9 pubmed
    b>Menogaril was administered to 40 patients with advanced breast cancer who had not received anthracycline drugs previously...
  4. Buckner J, Edmonson J, Ingle J, Schaid D. Evaluation of menogaril in patients with metastatic sarcomas and no prior chemotherapy exposure. Am J Clin Oncol. 1989;12:384-6 pubmed
    b>Menogaril, an anthracycline analog of nogalamycin, is reported to have greater cytotoxicity against certain malignant cell lines and less cardiotoxicity in rabbits than doxorubicin...
  5. Sinha B, Atwell J, Politi P. Role of oxygen free radical formation in the mechanism of menogaril resistance in multidrug resistant tumor cells. Chem Biol Interact. 1990;76:89-99 pubmed
    The mechanisms of action and resistance to menogaril, a clinically active anthracycline antitumor drug, were evaluated in sensitive and doxorubicin-selected multidrug resistant human breast tumor (MCF-7) cell lines...
  6. Dodion P, de Valeriola D, Crespeigne N, Peeters B, Wery F, van Berchem C, et al. Phase I clinical trial of oral menogaril administered on three consecutive days. Acta Oncol. 1988;27:517-20 pubmed
    Eighteen adult patients with solid tumors were treated with oral menogaril, a new anthracycline antibiotic active against human breast cancer after intravenous administration...
  7. Sugimoto Y, Matsuo K, Takeda S, Yamada Y, Tsukagoshi S. [Antitumor activities of orally administered 7-con-0-methylnogarol (TUT-7)]. Gan To Kagaku Ryoho. 1990;17:353-8 pubmed
    ..Base on above results, we concluded that oral administration is one of the useful route of TUT-7 administration. ..
  8. Ohashi K, Hara H, Takahashi F, Aso R, Akimoto T, Nakama K. [Pharmacokinetic studies of menogaril (TUT-7) with rats]. Gan To Kagaku Ryoho. 1992;19:1825-9 pubmed
    b>Menogaril (TUT-7) is a novel antitumor antibiotic belonging to anthracyclines...
  9. Stewart D, Eisenhauer E, Skillings J, Pritchard K, Buckman R, Vandenberg T, et al. Phase II study of oral menogaril as first line chemotherapy for advanced breast cancer: a National Cancer Institute of Canada Clinical Trials Group study. Ann Oncol. 1992;3:201-4 pubmed
    The National Cancer Institute of Canada (NCIC) Clinical Trials Group conducted a phase II study of weekly oral menogaril as first-line therapy in 51 patients with incurable, metastatic or locally advanced breast cancer...
  10. Stewart D, Aitken S, Verma S, Maroun J, Robillard L, Touchie M, et al. Phase I study of oral menogaril administered daily for 14 consecutive days. Ann Oncol. 1992;3:401-3 pubmed
    Twenty-eight patients were treated with oral menogaril daily x 14 every 4 weeks. Granulocytopenia was dose-limiting at 50-60 mg/m2 per day. Neutropenic fever occurred in one patient...
  11. Long H, Hauge M, Therneau T, Buckner J, Frytak S, Hahn R. Phase II evaluation of menogaril in patients with advanced hypernephroma. Invest New Drugs. 1991;9:261-2 pubmed
    Fifteen patients with advanced renal cell carcinoma were treated with Menogaril, 200 mg/m2 by one-hour, intravenous infusion at four-week intervals. No objective regressions were observed...
  12. Long H, Laurie J, Wieand H, Edmonson J, Levitt R, Krook J, et al. A phase II evaluation of menogaril in cisplatin-refractory advanced ovarian carcinoma. A collaborative trial of the North Central Cancer Treatment Group and the Mayo Clinic. Cancer. 1991;68:730-2 pubmed
    ..epithelial ovarian carcinoma (in whom prior chemotherapy with a platinum-based regimen failed) were treated with menogaril 200 mg/m2 intravenously every 4 weeks in a Phase II trial. Partial responses were seen in two of 19 (10...
  13. Skillings J, Cripps C, Eisenhauer E, Pater J, Verma S, Walde D. A phase II study of menogaril in low-grade non-Hodgkin's lymphoma. An NCI Canada Clinical Trials Group study. Invest New Drugs. 1991;9:79-82 pubmed
    The NCI Canada Clinical Trials Group conducted a phase II study of menogaril given intravenously every 4 weeks in low-grade non-Hodgkin's lymphoma. Fifteen of 26 eligible patients had had no prior therapy...
  14. Muggia F, Green M. New anthracycline antitumor antibiotics. Crit Rev Oncol Hematol. 1991;11:43-64 pubmed
    ..It is likely that these modifications will lead to an expanding therapeutic spectrum for these already widely useful drugs. ..
  15. Sternberg C, Magill G, Cheng E, Hollander P. Phase II trial of menogarol in the treatment of advanced adenocarcinoma of the pancreas. Am J Clin Oncol. 1988;11:174-6 pubmed
    ..No patients responded. At this dosage and schedule, there is no role for menogarol in the treatment of advanced pancreatic adenocarcinoma. ..
  16. Cruz J, Case L, Dalton H, Ramseur W, Richards F, Jackson D, et al. Menogaril in the treatment of relapsed multiple myeloma. A phase II trial of the Cancer Center of Wake Forest University. Invest New Drugs. 1992;10:35-7 pubmed
    Fifteen patients with relapsed multiple myeloma (MM) were treated with menogaril 160 mg/m2 intravenously (IV) every 28 days...
  17. Aaron C, Sorg R, Zimmer D. The mouse bone marrow micronucleus test: evaluation of 21 drug candidates. Mutat Res. 1989;223:129-40 pubmed
    ..The remaining 17 compounds were classified as negative in the assay. In general the results of the micronucleus test agreed with the results of other genetic toxicology assays on this group of compounds. ..
  18. Obasaju C, Manola J, Hudes G, Khandekar J, Citrin D, Carbone P, et al. Phase II evaluation of menogaril in advanced prostate cancer: Eastern Cooperative Oncology Group EST P-A885. Am J Clin Oncol. 2001;24:150-4 pubmed
    b>Menogaril is a semisynthetic anthracycline that is less cardiotoxic than doxorubicin in a preclinical model. We conducted a phase II trial to determine the activity of menogaril in hormone-refractory prostate cancer...
  19. Satoh H, Taguchi H, Yahagi S. [Antitumor spectrum of TUT-7 on rat ascitic hepatoma]. Gan To Kagaku Ryoho. 1990;17:287-91 pubmed
    ..A marked antitumor effect was observed in most tumor lines, and the activity was assumed to be better than adriamycin. ..
  20. Eisenhauer E, Pritchard K, Perrault D, Verma S, Pater J. Activity of intravenous menogaril in patients with previously untreated metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study. Invest New Drugs. 1990;8:283-7 pubmed
    We have carried out a phase II study of intravenous menogaril given every four weeks in a group of patients with breast cancer who had received no prior chemotherapy for metastatic disease...
  21. Sim S, Gatto B, Yu C, Liu A, Li T, Pilch D, et al. Differential poisoning of topoisomerases by menogaril and nogalamycin dictated by the minor groove-binding nogalose sugar. Biochemistry. 1997;36:13285-91 pubmed
    ..Using purified mammalian topoisomerases, menogaril is shown to poison topoisomerase II but not topoisomerase I...
  22. Stewart D, Verma S, Maroun J, Robillard L, Earhart R. Phase I study of oral menogaril administered on a once weekly schedule. Invest New Drugs. 1990;8:43-52 pubmed
    Forty-seven patients with solid tumors were treated on a phase I study of menogaril administered by mouth once per week...
  23. Peng R, VanNieuwenhze M. A model study for constructing the DEF-benzoxocin ring system of menogaril and nogalamycin via a reductive Heck cyclization. Org Lett. 2012;14:1962-5 pubmed publisher
    A novel reductive Heck cyclization approach was developed in order to construct a model DEF-benzoxocin ring system that is present in nogalamycin, menogaril, and related anthracycline antitumor antibiotics.
  24. Kucuk O, Kilton L, Wade J, Blough R, Benson A. Phase II trial of menogaril in patients with previously treated multiple myeloma or chronic lymphocytic leukemia. Am J Clin Oncol. 2000;23:379-83 pubmed
    b>Menogaril is a semisynthetic anthracycline with relative lack of cardiotoxicity...
  25. Adams W, McGovren J, Dalm E, Brewer J, Hosley J. Pharmacokinetics and systemic bioavailability of menogaril, an anthracycline antitumor agent, in the mouse, dog, and monkey. Cancer Res. 1989;49:6328-36 pubmed
    b>Menogaril is an antitumor agent of the anthracycline type which is less cardiotoxic than doxorubicin in a chronic rabbit model and is active in experimental tumor systems when given by p.o. or parenteral routes...
  26. Bichay T, Adams E, Inch W, Adams W, Brewer J, Bhuyan B. HPLC and flow cytometric analyses of uptake of adriamycin and menogaril by monolayers and multicell spheroids. Sel Cancer Ther. 1990;6:153-66 pubmed
    We have used both HPLC and flow cytometry to measure and compare the uptake of two anthracyclines, menogaril (MEN) and Adriamycin (ADR), in V79 Chinese hamster lung fibroblasts grown as monolayers and as 650 microns multicell spheroids...
  27. Kennedy M, Donehower R, Grochow L, Ettinger D, Fetting J, Abeloff M. Phase II trial of menogaril as initial chemotherapy for metastatic breast cancer. Invest New Drugs. 1990;8:289-94 pubmed
    ..metastatic breast cancer previously untreated with chemotherapy were entered on a phase II trial of intravenous menogaril, a new anthracycline derivative. Treatment was given at 140 mg/m2 on days 1 and 8 of each 28 day cycle...
  28. Badiner G, Moy B, Smith K, Tarpley W, Groppi V, Bhuyan B. P388 leukaemia cells resistant to the anthracycline menogaril lack multidrug resistant phenotype. Br J Cancer. 1990;62:378-84 pubmed
    b>Menogaril is an anthracycline presently in Phase II clinical trials...
  29. Stephens R, Goodman P, Crawford E, Spicer C, Lowe B, Ahmann F, et al. Evaluation of menogaril in renal cell carcinoma. A Southwest Oncology Group phase II study (8504). Invest New Drugs. 1990;8 Suppl 1:S69-71 pubmed
    The Southwest Oncology Group (SWOG) studied the response rate and toxicity of menogaril (200 mg/m2 i.v. q 28 days) in patients with advanced metastatic renal cell carcinoma...
  30. Vance R, Crowley J, Macdonald J, Ahmann F. Phase II evaluation of menogaril (NSC-269148) in non-small cell lung carcinoma. A Southwest Oncology Group study. Invest New Drugs. 1991;9:73-5 pubmed
    Forty-five patients with non-small cell lung cancer were treated in a phase II trial with menogaril 200 mg/m2 IV every twenty-eight days by a one-hour infusion...
  31. Egorin M, Conley B, Forrest A, Zuhowski E, Sinibaldi V, Van Echo D. Phase I study and pharmacokinetics of menogaril (NSC 269148) in patients with hepatic dysfunction. Cancer Res. 1987;47:6104-10 pubmed
    We performed a phase I study of menogaril to determine if dosage reduction was required in patients with hepatic dysfunction and if the relationship between pharmacokinetics and leukopenia, previously defined in patients with normal ..
  32. Boven E, Schluper H, Erkelens C, Pinedo H. Doxorubicin compared with related compounds in a nude mouse model for human ovarian cancer. Eur J Cancer. 1990;26:983-6 pubmed
    ..cancer lines grown in nude mice were used to compare the activity of doxorubicin, epirubicin, mitoxantrone and menogaril. The tumour lines were different in histological subtype, tumour doubling time and sensitivity to doxorubicin...
  33. Hudis C, Kelsen D. Menogaril in the treatment of malignant mesothelioma: a phase II study. Invest New Drugs. 1992;10:103-6 pubmed
    b>Menogaril is a new semisynthetic anthracycline agent derived from the antitumor antibiotic Nogalomycin...